Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia

Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia

Abstract A subcutaneous formulation of the anti‐CD20 antibody rituximab has been developed. Fixed‐dose subcutaneous rituximab delivers noninferior serum trough concentrations (Ctrough), ensuring similar target saturation and comparable efficacy/safety, to intravenous rituximab, but with simplified a...

Full description

Saved in:
Bibliographic Details
Main Authors: Ekaterina Gibiansky, Leonid Gibiansky, Clarisse Chavanne, Nicolas Frey, Candice Jamois
Format: article
Language:EN
Published: Wiley 2021
Subjects:
Therapeutics. Pharmacology
RM1-950
Online Access:https://doaj.org/article/96de8a1a1020405cb52160c9fa76dd90
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items